Fig. 1.
Generation and signaling pathways of some key lipid mediators in bone, muscle, and bone-muscle cross-talk. AEA, arachidonoyl ethanolamide; 2-AG, 2-arachidonoyl glycerol; CB, cannabinoid receptor; COX, cyclooxygenase; cPLA2, cytosolic phospholipase A2; DAGs, diacylglycerols; DHA, docosahexaenoic acid; 10,17-DiHDoHE, 10,17-dihydroxy-docosahexaenoic acid; DP, prostaglandin D2 receptor; EP, prostaglandin E2 receptor; EPA, eicosapentaenoic acid; FLAP, 5-lipoxygenase activating protein; FP, prostaglandin F2α receptor; 7-HDoHE, 7-hydroxy docosahexaenoic acid; IP, prostaglandin I2 receptor; LOX, lipoxygenase; LPC, lysophosphatidylcholine; LTA4, leukotriene A4; LTB4, leukotriene B4; LTC4, leukotriene C4; LTD4, leukotriene D4; LXA4, lipoxin A4; MaRs, maresins; NArPE, N-arachidonoyl phosphatidylethanolamine; OEA, oleoylethanolamide; PEA, palmitoylethanolamide; PD1, protectin D1; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGF2α, prostaglandin F2α; PGH2, prostaglandin H2; PGI2, prostaglandin I2; PPARs, proliferator-activated receptors; RvD1, resolvin D1; RvE1, resolvin E1; TG, triglycerides; TP, thromboxane receptor; TXA2, thromboxane A2